Pancras C.W. Hogendoorn

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.1K citations · Full text

Metastatic Soft-tissue Sarcoma, Versus Intensified Doxorubicin, Oncology +7

<i>IDH1</i> and <i>IDH2</i> mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Maria Fernanda Amary, Krisztian Bacsi, Francesca Maggiani et al. · The Journal of Pathology · 2011 · 966 citations · Full text

Cartilaginous Tumours, Genetics, Pathology +25

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

Isabelle Ray‐Coquard, Claire Cropet, M. van Glabbeke et al. · Cancer Research · 2009 · 780 citations · Full text

Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pancras C.W. Hogendoorn, Nick Athanasou, S. Bielack et al. · Annals of Oncology · 2010 · 716 citations · Full text

Bone Sarcomas, Surgical Oncology, Medicine +2

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Sigbjørn Smeland, Stefan Bielack, Jeremy Whelan et al. · European Journal of Cancer · 2019 · 700 citations · Full text